Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Medison Pharma Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (6)
Australian Public Assessment Report (AusPAR) (2)
Prescription medicine registration (2)
Prescription medicine decision summary (1)

Date

2024 (7)
2023 (1)
2022 (2)
2020 (1)

Results for "[search-keyword]"

Search

Sponsor content

11 result(s) found, displaying 11 to 11

LIBTAYO cemiplimab 350 mg concentrate for solution for infusion (320609)

17 July 2020

ARTG

Australian Register of Therapeutic Goods (ARTG) information for LIBTAYO cemiplimab 350 mg concentrate for solution for infusion.

Pages

First page
Previous page
Page 1
Current page 2

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.

Medison Pharma Australia Pty Ltd

Type

Date

LIBTAYO cemiplimab 350 mg concentrate for solution for infusion (320609)

Help us improve the Therapeutic Goods Administration site